39 results
8-K
EX-99.1
UNCY
Unicycive Therapeutics Inc
14 Nov 23
Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update
4:42pm
, due to an upfront payment for a licensing agreement entered into with Lee’s Pharmaceutical (HK) Limited in July 2022.
Research and Development (R&D … ,
Licensing revenues:
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other
8-K
EX-99.1
8gt5j
6 Sep 23
Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD
9:16am
8-K
7ejsh
6 Sep 23
Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD
9:16am
8-K
EX-99.1
0123rq1pcf00
14 Aug 23
Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update
9:19pm
8-K
EX-99.1
nezar
16 May 23
Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update
10:30am
8-K
EX-99.1
i96ny
31 Mar 23
Unicycive Announces Full Year 2022 Financial Results and Provides Business Update
7:47am
8-K
EX-99.1
gp604zes6upsk1yui0o0
14 Nov 22
Unicycive Announces Third Quarter Financial Results and Provides Business Update
9:49am
S-3
iv560ksijji07e7jbqvu
15 Aug 22
Shelf registration
6:20pm
8-K
EX-99.1
w9t5vku987
15 Aug 22
Unicycive Announces Second Quarter Financial Results and Provides Business Update
6:18pm
8-K
EX-99.1
w5lyuelzkcsn
18 Jul 22
Expands and accelerates Renazorb opportunity in important markets for patients with hyperphosphatemia through local partner with deep domain expertise
4:15pm